Vertex's $259,000 Cystic Fibrosis Drug Approved

Vertex’s cystic-fibrosis drug Orkambi, which treats the most common mutation of the disease, received U.S. regulatory approval on Thursday.

Source: WSJ.com: Health - July 3, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news